Provided by Tiger Trade Technology Pte. Ltd.

Prelude Therapeutics Inc

4.38
+0.28006.83%
Post-market: 4.30-0.0800-1.83%16:34 EDT
Volume:3.69M
Turnover:16.09M
Market Cap:348.84M
PE:-4.42
High:4.38
Open:4.08
Low:4.02
Close:4.10
52wk High:5.54
52wk Low:0.7500
Shares:79.64M
Float Shares:8.06M
Volume Ratio:7.58
T/O Rate:45.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9899
EPS(LYR):-1.2929
ROE:-95.25%
ROA:-39.69%
PB:5.80
PE(LYR):-3.39

Loading ...

Prelude Therapeutics Highlights Promising PRT13722 Preclinical Results

TIPRANKS
·
Apr 20

Prelude Therapeutics presents new preclinical data from PRT13722 study

TIPRANKS
·
Apr 20

Prelude Therapeutics Inc - Pricing of 18.01 Mln Shares of Common Stock at $4.44 per Share

THOMSON REUTERS
·
Apr 20

Press Release: Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering

Dow Jones
·
Apr 20

Prelude Therapeutics targets mid-2026 IND filing for PRT13722 breast cancer trial

Reuters
·
Apr 20

Press Release: Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer

Dow Jones
·
Apr 15

Prelude Therapeutics Chief Business Officer Sean P. Brusky files initial beneficial ownership statement

Reuters
·
Mar 20

Prelude Therapeutics management to meet with Citizens

TIPRANKS
·
Mar 19

Prelude Therapeutics to present PRT13722 preclinical poster at AACR Annual Meeting 2026

Reuters
·
Mar 18

Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting

GlobeNewswire
·
Mar 18

Prelude Therapeutics Is Maintained at Market Outperform by Citizens

Dow Jones
·
Mar 11

Prelude Therapeutics price target raised to $6 from $3 at Citizens

TIPRANKS
·
Mar 11

Prelude Therapeutics Reports 2025 Results, Highlights JAK2 Program

TIPRANKS
·
Mar 10

Prelude Therapeutics Q4 EPS $(0.20) Misses $(0.03) Estimate, Sales $5.640M Miss $35.000M Estimate

Benzinga
·
Mar 10

Prelude Therapeutics reports $99.5 mln net loss for 2025

Reuters
·
Mar 10

BRIEF-Prelude Therapeutics FY EPS USD -1.29

Reuters
·
Mar 10

Press Release: Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026

Dow Jones
·
Mar 10

Prelude Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview

Reuters
·
Mar 06

Walmart, DoorDash And 3 Stocks To Watch Heading Into Thursday

Benzinga_recent_news
·
Feb 19

Sana Biotechnology Names Brian Piper Chief Financial Officer

Reuters
·
Feb 17